The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices

Cardiome Pharma Corp Hits New 20-day High

Cardiome Pharma Corp closed up Friday by $0.08 or 1.14% to $7.10 and setting a new 20-day high. Over the last five days, shares have gained 3.50%, but are down 36.21% for the last year to date. Shares have underperformed the S&P TSX by 40.31% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$1.52
Updated July 22 3:55 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-96.92%

Although this company's net profit margin is negative, it is above the industry average and implies that Cardiome Pharma Corp is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.24%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7556
Total other revenue--------
Total revenue7556
Gross profit6245
Total cost of revenue1311
Total operating expense8121013
Selling / general / administrative6888
Research & development0003
Depreciation / amortization1111
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-1-7-5-7
Interest income (expense), net non-operating00-1-1
Gain (loss) on sale of assets--------
Other--------
Income before tax-1-8-6-7
Income after tax-1-7-6-7
Income tax, total0000
Net income-1-7-6-7
Total adjustments to net income--------
Net income before extra. items-1-7-6-7
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1-7-6-7
Inc. avail. to common incl. extra. items-1-7-6-7
Diluted net income-1-7-6-7
Dilution adjustment--------
Diluted weighted average shares20201917
Diluted EPS excluding extraordinary itemsvalue per share-0.06-0.37-0.31-0.43
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.06-0.37-0.31-0.43